The review article by Scherlinger et al. delves into the crucial role platelets play in the pathogenesis of immune-mediated inflammatory diseases (IMIDs). These diseases, characterized by excessive and uncontrolled inflammation and thrombosis, result in significant organ damage, morbidity, and mortality. Traditionally known for their role in primary hemostasis, platelets are now recognized as vital components of the immune system.
Platelets in patients with IMIDs are activated by disease-specific factors, and this activation often reflects disease activity. Once activated, platelets produce soluble factors and directly interact with immune cells, promoting an inflammatory phenotype. This interaction leads to tissue injury and abnormal healing, resulting in fibrosis. The review summarizes various mechanisms of platelet activation, including their interaction with immune complexes through Fc receptors, binding by autoantibodies, and engagement of Toll-like receptors (TLRs). These processes amplify immune responses and contribute to the pathology of IMIDs.
Activated platelets release cytokines, chemokines, and damage-associated molecular patterns (DAMPs), further promoting inflammation. They also present antigens and interact with immune cells like neutrophils, monocytes, and dendritic cells, influencing their function and contributing to disease progression. The review highlights how targeting platelet activation and their interaction with the immune system presents novel therapeutic strategies for IMIDs.
The immunomodulatory properties of platelets, as discussed in this review, are closely aligned with the objectives of Novastem's stem cell therapies. Both approaches aim to regulate immune responses and promote tissue repair. Conditions such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis, which involve significant platelet activation and interaction with immune cells, could benefit from stem cell therapies. These therapies may complement the effects of platelet modulation by further enhancing immune regulation and facilitating tissue regeneration.
- Mechanism of Action: Platelets, upon activation, release various factors that promote inflammation, interact with immune cells, and contribute to tissue damage and fibrosis.
- Clinical Benefits: Understanding the role of platelets in IMIDs opens up new avenues for therapeutic intervention, potentially improving outcomes in diseases characterized by excessive inflammation and thrombosis.
- Potential for Broad Application: The insights gained from this review support the development of targeted therapies that can modulate platelet activity and interactions, offering broad applicability across various IMIDs.
#Platelets #ImmuneMediatedInflammatoryDiseases #Inflammation #Thrombosis #ImmuneCells #TissueDamage #StemCellTherapy
THE POWER BRINGS YOU BACK
The review article by Scherlinger et al. delves into the crucial role platelets play in the pathogenesis of immune-mediated inflammatory diseases (IMIDs). These diseases, characterized by excessive and uncontrolled inflammation and thrombosis, result in significant organ damage, morbidity, and mortality. Traditionally known for their role in primary hemostasis, platelets are now recognized as vital components of the immune system.
Platelets in patients with IMIDs are activated by disease-specific factors, and this activation often reflects disease activity. Once activated, platelets produce soluble factors and directly interact with immune cells, promoting an inflammatory phenotype. This interaction leads to tissue injury and abnormal healing, resulting in fibrosis. The review summarizes various mechanisms of platelet activation, including their interaction with immune complexes through Fc receptors, binding by autoantibodies, and engagement of Toll-like receptors (TLRs). These processes amplify immune responses and contribute to the pathology of IMIDs.
Activated platelets release cytokines, chemokines, and damage-associated molecular patterns (DAMPs), further promoting inflammation. They also present antigens and interact with immune cells like neutrophils, monocytes, and dendritic cells, influencing their function and contributing to disease progression. The review highlights how targeting platelet activation and their interaction with the immune system presents novel therapeutic strategies for IMIDs.
The immunomodulatory properties of platelets, as discussed in this review, are closely aligned with the objectives of Novastem's stem cell therapies. Both approaches aim to regulate immune responses and promote tissue repair. Conditions such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis, which involve significant platelet activation and interaction with immune cells, could benefit from stem cell therapies. These therapies may complement the effects of platelet modulation by further enhancing immune regulation and facilitating tissue regeneration.
#Platelets #ImmuneMediatedInflammatoryDiseases #Inflammation #Thrombosis #ImmuneCells #TissueDamage #StemCellTherapy